- Date2024-09-06
Publication of Review Result of the Fifth Pharmaceutical Reimbursement Evaluation Committee of 2022
□ The Health Insurance Review and Assessment Service (President Kim Sun-min) releases the results of the deliberations of the 5th Pharmaceutical Reimbursement Evaluation Committee in 2022 as follows.
○ Result of the review of the adequacy of the healthcare benefit for the pharmaceutical applied for assessment
|
Product |
Pharmaceutical company |
Efficacy and effectiveness |
Deliberation results |
|
Zolgensma Inj. (Onasemnogene abeparvovec) |
Novartis Korea Ltd |
Patient with spinal muscular atrophy (SMA) with a biallelic mutation in the SMN1 gene |
Reimbursement is adequate. *If healthcare benefit is pre- authorized, and patient-level performance-based risk sharing and total amount limit apply. |
|
Fexuclue Tab 40mg etc 4 product (Fexuprazan hydrochloride) |
Daewoong Pharmaceutical co. Ltd, Daewoongbio co. Ltd, Hanall Biopharma co. Ltd, In Therapeutics co. Ltd |
Treatment of erosive gastroesophageal reflux disease (GERD) |
Reimbursement is adequate when accepted at or below assessed value. |
|
Donepezil/Donesive Patch 87.5 175mg (Donepezil) |
CELLTRION Inc, icure pharmaceutical & cosmetics co. Ltd |
Treating symptoms of Alzheimer's type dementia |
Reimbursement is adequate when accepted at or below assessed value. |
|
Emgality 120 mg /Milliliter pre-filled pen,Pre-filled syringe (Galcanezumab, Recombinant DNA) |
Eli Lilly and Company Korea |
Prevention of migraine in adults |
Reimbursement is adequate. |
